Alemtuzumab

證據等級: L5

預測適應症: 10 個

Alemtuzumab: From B-Cell Malignancy / Multiple Sclerosis to Syndrome with Combined Immunodeficiency

One-Sentence Summary

Alemtuzumab is a humanized anti-CD52 monoclonal antibody with established global approvals for B-cell chronic lymphocytic leukaemia (B-CLL) and relapsing-remitting multiple sclerosis; it carries no regulatory registration in Taiwan. The TxGNN model’s highest-evidence prediction points to Syndrome with Combined Immunodeficiency, where alemtuzumab functions as a cornerstone reduced-intensity conditioning (RIC) agent prior to haematopoietic stem cell transplantation (HSCT), supported by 13 clinical trials and 12 publications at an evidence level of L2.

Quick Overview

Item	Content
Original Indication	Not registered in Taiwan (globally: B-CLL, relapsing-remitting multiple sclerosis)
Predicted New Indication	Syndrome with Combined Immunodeficiency
TxGNN Prediction Score	93.73%
Evidence Level	L2
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known clinical information, alemtuzumab (Campath-1H / Lemtrada) is a humanized IgG1κ monoclonal antibody that targets CD52, a glycoprotein expressed at high density on the surface of mature T lymphocytes, B lymphocytes, monocytes, and natural killer cells. Binding of alemtuzumab to CD52 triggers rapid and profound lymphodepletion through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptotic signalling. This mechanism is the basis of its efficacy in lymphocytic malignancies and its immune-modulating effect in multiple sclerosis.

In the context of syndrome with combined immunodeficiency — encompassing SCID and related primary immunodeficiency disorders — allogeneic HSCT is the only curative treatment. The fundamental challenge is preventing graft rejection without inflicting the severe organ toxicity of conventional myeloablative chemotherapy on patients who are already fragile, chronically infected, and often very young. By eliminating host CD52⁺ T and B cells before transplant, alemtuzumab creates the immunological “space” required for donor stem cell engraftment, while simultaneously reducing the risk of graft-versus-host disease (GvHD). This positions alemtuzumab as the immunological bridge that makes safer HSCT feasible in these vulnerable patients — a rationale that is direct, mechanistically coherent, and well-documented in transplant literature.

The repurposing signal is therefore not a novel off-target effect but a deliberate extension of alemtuzumab’s established lymphodepleting biology into the RIC-HSCT conditioning setting. Multiple published cohorts from major transplant centres document alemtuzumab-fludarabine-based RIC as a standard clinical approach for SCID and related PIDs, lending strong biological plausibility to the TxGNN prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01019876	Phase 2/3	Completed	38	Risk-adapted allogeneic SCT with RIC (including alemtuzumab) for mixed donor chimerism in non-malignant diseases including immunodeficiencies; highest-quality completed trial in this dataset
NCT00579137	Phase 1/2	Terminated	3	CD45 + alemtuzumab monoclonal antibody conditioning for allogeneic SCT in SCID and other PIDs using HLA-mismatched donors; terminated early — accrual reasons to be confirmed
NCT01182675	Phase 2	Terminated	7	Novel alemtuzumab + plerixafor/filgrastim HSCT protocol for children with SCID designed to avoid toxic chemotherapy conditioning; terminated — reason (safety vs. accrual) requires clarification
NCT01652092	N/A	Active, Not Recruiting	57	Standard-of-care HSCT treatment guideline for a broad range of primary immune deficiencies; largest accrual in this dataset despite lack of formal phase designation
NCT01962415	Phase 2	Recruiting	100	RIC with UCBT/BMT/PBSCT for paediatric patients and young adults ≤55 years with non-malignant disorders; alemtuzumab is one of the conditioning backbone options
NCT07284641	Phase 2	Recruiting	25	RIC HSCT with TBI for CVID and other primary immune regulatory disorders; directly addresses the combined immunodeficiency spectrum
NCT05463133	Phase 1/2	Recruiting	50	Alemtuzumab + busulfan + TBI conditioning for HSCT in chronic granulomatous disease; combined immunodeficiency-adjacent indication with cytokine antagonists co-intervention
NCT02512679	Phase 2	Terminated	20	Related-donor HSCT protocol covering genetic lymphohematological diseases including combined immune deficiency and Wiskott-Aldrich syndrome; terminated with limited follow-up data
NCT01821781	Phase 2	Active, Not Recruiting	20	RIC preparative regimen for immune function disorders maximising host immunosuppression to optimise donor engraftment
NCT04528355	N/A	Recruiting	50	Prospective outcomes study examining simplified alemtuzumab dosing strata in RIC-HSCT across paediatric and adult non-malignant disorders

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29155317	2018	Prospective Cohort	Biol Blood Marrow Transplant	Treosulfan + fludarabine + alemtuzumab conditioning in 160 UK children with PID; improved T-cell chimerism and lower toxicity versus treosulfan-cyclophosphamide arm
21325599	2011	Retrospective Cohort	Blood	Treosulfan conditioning in 70 PID children; alemtuzumab included; fludarabine arm demonstrated lower VOD incidence and better T-cell immune reconstitution
27543157	2016	Retrospective Cohort	Biol Blood Marrow Transplant	Alemtuzumab (1 mg/kg) + fludarabine + melphalan RIC vs myeloablative busulfan/cyclophosphamide/ATG for CGD; RIC showed reduced toxicity with comparable engraftment
23131490	2013	International Survey	Blood	Allogeneic HCT for XIAP deficiency (n=19); alemtuzumab-predominant RIC used in 11 patients; overall poor outcomes highlight continued need for optimised conditioning protocols
26073206	2015	Retrospective Cohort	Pediatr Transplant	HSCT for hyper-IgM syndrome due to CD40L defects (n=5); demonstrates curative potential of HSCT across the combined immunodeficiency spectrum
18940685	2008	Retrospective Cohort	Biol Blood Marrow Transplant	Campath-1H (alemtuzumab) + fludarabine sub-myeloablative regimen rescued SCT graft failure in 12 children including 4 with SCID; all achieved successful engraftment
19471859	2009	Case Report	Immunol Res	FOXP3⁺ regulatory T-cell reconstitution following alemtuzumab-conditioned BMT for IPEX syndrome; demonstrates durable immune reconstitution as a functional endpoint
11841458	2002	Case Report	Br J Haematol	Non-myeloablative alemtuzumab-based BMT in a 26-year-old adult with Wiskott-Aldrich syndrome; partial engraftment and immune restoration achieved — early feasibility signal in adult PID
35065305	2022	Case Report	Clin Immunol	Diagnostic workup of bare lymphocyte syndrome type II (novel RFXANK mutation, MHC class II deficiency) presenting as SCID-like phenotype; contextualises the diagnostic breadth of combined immunodeficiency
15590388	2004	Safety Report	Haematologica	Infectious toxicity profile of alemtuzumab; essential safety reference for its use in immunocompromised HSCT candidates

Taiwan Market Information

Alemtuzumab is not registered in Taiwan. No marketing authorizations are on record with the TFDA, and no approved indication text is available.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — humanized anti-CD52 monoclonal antibody (IgG1κ); profound lymphodepletion is the intended therapeutic mechanism, not non-selective DNA damage
Myelosuppression Risk	High — sustained, severe lymphopenia is the desired pharmacological effect; pancytopenia and markedly increased susceptibility to opportunistic infections (CMV, EBV, fungal) are expected sequelae
Emetogenicity Classification	Low — monoclonal antibodies carry minimal direct emetogenic potential; infusion-related reactions (rigors, fever, hypotension) are the more common acute adverse events
Monitoring Items	CBC with differential and lymphocyte subsets (CD4, CD8, NK), CMV and EBV viral loads (PCR), liver function tests, renal function, galactomannan / β-D-glucan (fungal surveillance), and donor chimerism post-HSCT
Handling Protection	Follow institutional protocols for biological agents and cytotoxic drugs; standard PPE required; consult pharmacy for preparation and administration guidelines

Safety Considerations

TFDA product insert (仿單) warnings, contraindications, and Taiwan-specific drug interaction data are not available for this evidence pack. Please refer to the current EMA Summary of Product Characteristics (SmPC) for Alemtuzumab (Lemtrada / MabCampath) for complete safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Alemtuzumab-based RIC conditioning for HSCT in combined immunodeficiency is backed by one completed Phase 2/3 trial (NCT01019876, n=38), multiple Phase 2 studies, and several retrospective multi-centre cohorts documenting its use as a standard lymphodepleting backbone — placing the overall evidence at L2. The mechanistic rationale (CD52-targeted lymphodepletion enabling donor stem cell engraftment with reduced GvHD risk) is direct, biologically sound, and clinically well-established at leading transplant centres worldwide.

To proceed, the following is needed:

Retrieve and parse the TFDA product insert (仿單) to establish Taiwan-specific warnings, contraindications, and precautions
Confirm mechanism of action data via DrugBank API query (DB00087) to complete the mechanistic dossier
Clarify the termination rationale for NCT00579137 (n=3) and NCT01182675 (n=7) — determine whether termination was due to safety signals or poor accrual
Conduct a structured comparison of alemtuzumab-based RIC versus ATG-based or thiotepa-based alternatives to define the optimal conditioning backbone by SCID sub-type
Establish route-of-administration compatibility and pharmacy infrastructure for IV alemtuzumab in the HSCT conditioning setting in Taiwan
Define patient eligibility boundaries (age, donor match grade, specific PID genotype) based on sub-group outcomes from existing cohort data
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.